Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioChaperone Combo 75/25 Dose-linearity in T2DM
NCT03180710Phase 1Completed
- Sponsor
- Adocia
- Start
- Jun 2017
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BioChaperone glargine lispro in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Adocia. Primary endpoints: Area Under the Curve last_total and Maximum Concentration total. Started Jun 2017; status: completed.
02
Drugs
BioChaperone glargine lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03180710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03180710.